Literature DB >> 1339393

Architecture of the canine IDUA gene and mutation underlying canine mucopolysaccharidosis I.

K P Menon1, P T Tieu, E F Neufeld.   

Abstract

Mucopolysaccharidosis I (MPS I) is a lysosomal storage disease caused by deficiency of alpha-L-iduronidase. In addition to the well-known human forms (Hurler, Hurler/Scheie, and Scheie syndromes), there exists a canine model of the disease. By using previously described canine cDNA encoding alpha-L-iduronidase as a probe, the canine IDUA gene has been cloned and characterized. It contains 14 exons spread over 13 kb. An unusual GC dinucleotide was found at the donor splice site of intron 11. A transcriptional start site was identified by primer extension 177 bp upstream of the initiator AUG codon. The upstream region was found to be similar to the promoter region of many housekeeping genes: it is GC rich and has seven potential Sp1 binding sites but no TATA box or CAAT motif. The mutation in canine MPS I was localized to the area of intron 1 by RT-PCR, identified by sequence analysis of amplified genomic DNA, and confirmed by restriction analysis; it is a G-->A transition in the donor splice site of intron 1. The mutation causes retention of intron 1 in the RNA and creates a premature termination codon at the exon-intron junction.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1339393     DOI: 10.1016/s0888-7543(05)80182-x

Source DB:  PubMed          Journal:  Genomics        ISSN: 0888-7543            Impact factor:   5.736


  38 in total

1.  Optimized transduction of canine paediatric CD34(+) cells using an MSCV-based bicistronic vector.

Authors:  S E Suter; T A Gouthro; P A McSweeney; R A Nash; M E Haskins; P J Felsburg; P S Henthorn
Journal:  Vet Res Commun       Date:  2006-11       Impact factor: 2.459

2.  Enzyme replacement therapy from birth in a feline model of mucopolysaccharidosis type VI.

Authors:  A C Crawley; K H Niedzielski; E L Isaac; R C Davey; S Byers; J J Hopwood
Journal:  J Clin Invest       Date:  1997-02-15       Impact factor: 14.808

3.  Intra-articular enzyme replacement therapy with rhIDUA is safe, well-tolerated, and reduces articular GAG storage in the canine model of mucopolysaccharidosis type I.

Authors:  Raymond Y Wang; Afshin Aminian; Michael F McEntee; Shih-Hsin Kan; Calogera M Simonaro; William C Lamanna; Roger Lawrence; N Matthew Ellinwood; Catalina Guerra; Steven Q Le; Patricia I Dickson; Jeffrey D Esko
Journal:  Mol Genet Metab       Date:  2014-06-06       Impact factor: 4.797

Review 4.  Enzyme replacement therapy in mucopolysaccharidosis type I: progress and emerging difficulties.

Authors:  J E Wraith
Journal:  J Inherit Metab Dis       Date:  2001-04       Impact factor: 4.982

5.  Prolonged Expression of Secreted Enzymes in Dogs After Liver-Directed Delivery of Sleeping Beauty Transposons: Implications for Non-Viral Gene Therapy of Systemic Disease.

Authors:  Elena L Aronovich; Kendra A Hyland; Bryan C Hall; Jason B Bell; Erik R Olson; Myra Urness Rusten; David W Hunter; N Matthew Ellinwood; R Scott McIvor; Perry B Hackett
Journal:  Hum Gene Ther       Date:  2017-05-19       Impact factor: 5.695

6.  Enzyme replacement in a canine model of Hurler syndrome.

Authors:  R M Shull; E D Kakkis; M F McEntee; S A Kania; A J Jonas; E F Neufeld
Journal:  Proc Natl Acad Sci U S A       Date:  1994-12-20       Impact factor: 11.205

Review 7.  Large animal models of neurological disorders for gene therapy.

Authors:  Christine Gagliardi; Bruce A Bunnell
Journal:  ILAR J       Date:  2009

Review 8.  Gene therapy for lysosomal storage diseases (LSDs) in large animal models.

Authors:  Mark Haskins
Journal:  ILAR J       Date:  2009

9.  Molecular analysis of Hurler syndrome in Druze and Muslim Arab patients in Israel: multiple allelic mutations of the IDUA gene in a small geographic area.

Authors:  G Bach; S M Moskowitz; P T Tieu; A Matynia; E F Neufeld
Journal:  Am J Hum Genet       Date:  1993-08       Impact factor: 11.025

10.  Radiographic evaluation of bones and joints in mucopolysaccharidosis I and VII dogs after neonatal gene therapy.

Authors:  Ramin Sedaghat Herati; Van W Knox; Patricia O'Donnell; Marina D'Angelo; Mark E Haskins; Katherine P Ponder
Journal:  Mol Genet Metab       Date:  2008-08-15       Impact factor: 4.797

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.